Regulation of FBXO4-mediated ICAM-1 protein stability in metastatic breast cancer

Jae-Hyeok Kang; Mi-Young Choi; Yan-Hong Cui; Neha Kaushik; Nizam Uddin; Ki-Chun Yoo; Min-Jung Kim; Su-Jae Lee

doi:10.18632/oncotarget.20912

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Regulation of FBXO4-mediated ICAM-1 protein stability in metastatic breast cancer

Jae-Hyeok Kang, Mi-Young Choi, Yan-Hong Cui, Neha Kaushik, Nizam Uddin, Ki-Chun Yoo, Min-Jung Kim and Su-Jae Lee _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:83100-83113. https://doi.org/10.18632/oncotarget.20912

Metrics: PDF 1615 views | HTML 2306 views | ?

Abstract

Jae-Hyeok Kang1,*, Mi-Young Choi1,*, Yan-Hong Cui1, Neha Kaushik1, Nizam Uddin2, Ki-Chun Yoo1, Min-Jung Kim3 and Su-Jae Lee1

1Department of Life Science, Research Institute for Natural Sciences, Hanyang University, Seoul, Korea

2Centre of Excellence in Molecular Biology (CEMB), University of The Panjab, Lahore, Pakistan

3Laboratory of Radiation Exposure and Therapeutics, National Radiation Emergency Medical Center, Korea Institute of Radiological and Medical Sciences, Seoul, Korea

*These authors have contributed equally to this work

Correspondence to:

Su-Jae Lee, email: [email protected]

Keywords: intercellular adhesion molecule-1, E3 ligase, FBXO4, stability, metastatic breast cancer

Received: July 21, 2017 Accepted: August 27, 2017 Published: September 15, 2017

ABSTRACT

Advanced or progressive cancers share common traits such as altered transcriptional modulation, genetic modification, and abnormal post-translational regulation. These processes influence protein stability and cellular activity. Intercellular adhesion molecule-1 (ICAM-1) is involved in the malignant progression of various human cancers, including breast, liver, renal, and pancreatic cancers, but protein stability has not been deal with in metastatic breast cancer. Additionally, the relevance of the stability maintenance of ICAM-1 protein remains obscure. Here, we identified a novel interaction of E3 ligase FBXO4 that is specifically presented to ICAM-1. To understand how FBXO4 modulates ICAM-1 stability, we investigated ICAM-1-overexpressing or knockdown metastatic/non-metastatic breast cancers. ICAM-1 was found to influence tumor progression and metastasis, whereas FBXO4 regulated aggressive tumorigenic conditions. These results demonstrate that FBXO4 is a major regulator of ICAM-1 stability and that alterations in the stability of ICAM-1 can influence therapeutic outcome in metastatic cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20912

Publication Alerts

Research Papers:

Regulation of FBXO4-mediated ICAM-1 protein stability in metastatic breast cancer

Abstract